Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature.
Photodermatol Photoimmunol Photomed
; 34(3): 194-199, 2018 May.
Article
em En
| MEDLINE
| ID: mdl-29171925
ABSTRACT
BACKGROUND:
Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging, and outcomes are often disappointing. Omalizumab is an anti-IgE, currently approved for treatment of chronic spontaneous urticaria. We sought to evaluate therapy with omalizumab in refractory SU and describe predictive factors for response. MATERIALS/METHODS:
Patients with refractory SU under treatment with omalizumab were included in this study. Clinical outcome was evaluated using the Urticaria Activity Score 7 (UAS7), Dermatology Life Quality Index (DLQI) and Pruritus Visual Analogue Scale (VAS). Complete clinical response (CCR) was defined as having an UAS7 = 0, DLQI <6 and VAS = 0. Phototesting was performed and compared to baseline. We performed a PubMed search to identify reported cases of SU in adults treated with omalizumab, analysing their characteristics in order to predict response to omalizumab.RESULTS:
Eight patients were included. Median age was 45.5 years (range, 23-64). Light spectrum most commonly implicated was UV-A. Clinicaloutcomes:
89% (7/8) achieved CCR with omalizumab. Phototesting was normal in 42.8% (3/7) of them. In our review, we identified 38 patients (including the current case series), and 68.4% showed favourable outcomes with omalizumab. Median time since onset of SU was lower in responders.CONCLUSIONS:
Omalizumab can be an effective treatment in refractory SU.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Luz Solar
/
Urticária
/
Omalizumab
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Systematic_reviews
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Photodermatol Photoimmunol Photomed
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
DERMATOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Espanha